Published in Naunyn Schmiedebergs Arch Pharmacol on October 01, 1980
Clonidine activates membrane potassium conductance in myenteric neurones. Br J Pharmacol (1981) 1.39
Capsaicin-sensitive afferents activate a sympathetic intestinointestinal inhibitory reflex in dogs. J Physiol (1990) 0.82
Evidence for functional alpha 2D-adrenoceptors in the rat intestine. Br J Pharmacol (1996) 0.75
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem (2000) 4.36
Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J (1999) 3.13
Centrally mediated decrease in sympathetic tone induced by 2(2,6-dichlorophenylamino)-2 imidazoline (S.T. 155, Catapresan). Eur J Pharmacol (1967) 2.73
Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol (2000) 2.41
Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res (1994) 2.34
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Topoisomerase I-mediated DNA damage. Adv Cancer Res (2001) 2.16
Evidence for an alpha-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane. Eur J Pharmacol (1971) 2.15
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med (2001) 2.04
Gadd45, a p53-responsive stress protein, modifies DNA accessibility on damaged chromatin. Mol Cell Biol (1999) 1.97
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res (1989) 1.94
Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J Biol Chem (1999) 1.91
Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci U S A (1993) 1.91
Ca2+ triggers massive exocytosis in Chinese hamster ovary cells. EMBO J (1996) 1.80
Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst (1994) 1.79
Eukaryotic DNA topoisomerases I. Biochim Biophys Acta (1995) 1.76
Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem (1991) 1.74
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res (1989) 1.71
Action of -adrenergic blocking drugs on the sympathetic centres and their interactions with the central sympatho-inhibitory effect of clonidine. Arzneimittelforschung (1973) 1.71
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol Pharmacol (1998) 1.69
Human mitochondrial topoisomerase I. Proc Natl Acad Sci U S A (2001) 1.67
A universal spine tester for in vitro experiments with muscle force simulation. Eur Spine J (1994) 1.65
Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem (1997) 1.63
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res (1999) 1.62
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst (1999) 1.61
Simultaneous determination of neuromuscular block at the larynx, diaphragm, adductor pollicis, orbicularis oculi and corrugator supercilii muscles. Br J Anaesth (2000) 1.58
Cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155). II. Central sympathetic structures. Eur J Pharmacol (1968) 1.56
Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem (1997) 1.55
[Pharmacologic study of fenfluramine and its optical isomers]. Arch Int Pharmacodyn Ther (1966) 1.55
Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res (1990) 1.50
Contig assembly of bacterial artificial chromosome clones through multiplexed fluorescence-labeled fingerprinting. Genomics (1999) 1.48
Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol (1994) 1.46
Retroperitoneal lymphangiectasia associated with bilateral renal vein thrombosis. Nephrol Dial Transplant (1997) 1.45
Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res (1997) 1.44
Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res (1989) 1.43
bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res (1993) 1.43
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors. J Med Chem (2000) 1.42
Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry (1986) 1.39
A technique for recording sympathetic nerve activity in unanaesthetized dogs. Neuropharmacology (1974) 1.38
Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res (1995) 1.36
Health care expenditure in the last months of life. J Health Econ (2000) 1.35
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res (2001) 1.34
Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol (1990) 1.32
Translation in vitro of rat brain messenger RNA coding for tubulin and actin. Proc Natl Acad Sci U S A (1975) 1.31
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 1.31
Intermolecular disintegration and intramolecular strand transfer activities of wild-type and mutant HIV-1 integrase. Nucleic Acids Res (1994) 1.29
Sedative effects of alpha-sympathomimetic drugs and their antagonism by adrenergic and cholinergic blocking drugs. Eur J Pharmacol (1971) 1.26
Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res (1995) 1.26
Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor. Proc Natl Acad Sci U S A (1998) 1.25
Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. Biochemistry (1997) 1.23
Hydroxylated aromatic inhibitors of HIV-1 integrase. J Med Chem (1995) 1.22
Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole A/Giudicelli JF, Schmitt H, Boissier JR: Studies on dl-4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB 46), a new potent beta adrenergic blocking drug. J Pharmacol Exp Ther (1969) 1.22
Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem (1997) 1.21
Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol (1995) 1.21
Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry (1990) 1.20
Activation of transcription factor AP-2 mediates UVA radiation- and singlet oxygen-induced expression of the human intercellular adhesion molecule 1 gene. Proc Natl Acad Sci U S A (1996) 1.19
Mechanism of inhibition of HIV-1 integrase by G-tetrad-forming oligonucleotides in Vitro. J Biol Chem (2000) 1.18
DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res (1987) 1.17
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol (2000) 1.17
Depletion of poly(ADP-ribose) polymerase by antisense RNA expression results in a delay in DNA strand break rejoining. J Biol Chem (1992) 1.17
Central cardiovascular effects of morphinomimetic peptides in dogs. Eur J Pharmacol (1977) 1.16
Coumarin-based inhibitors of HIV integrase. J Med Chem (1997) 1.16
Host site selection for concerted integration by human immunodeficiency virus type-1 virions in vitro. Virology (1997) 1.16
p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine. Oncogene (2006) 1.15
[Clinical studies on the effect of a new oral antidiabetic agent Glybenclamide (HB 419)]. Dtsch Med Wochenschr (1969) 1.15
In vitro human immunodeficiency virus type 1 integrase assays. Methods Enzymol (2001) 1.15
The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract (1992) 1.15
Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res (1991) 1.14
Antinociceptive effects of some alpha-sympathomimetic agents. Neuropharmacology (1974) 1.13
Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett (2001) 1.13
Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem (1999) 1.13
Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry (1996) 1.13
Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate. Proc Natl Acad Sci U S A (1994) 1.13
Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem Pharmacol (1982) 1.12
Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res (1996) 1.12
Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J Med Chem (1998) 1.12
T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1995) 1.11
Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang (1991) 1.11
Measurement of spin-transfer observables in p p-->Lambda Lambda at 1.637 GeV/c. Phys Rev Lett (2002) 1.09
Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage. Biochemistry (1985) 1.08
Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry (1995) 1.08
Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood (1993) 1.08
Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects. J Cardiovasc Pharmacol (1985) 1.08
Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res (1995) 1.07
The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia (1995) 1.07
Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry (1985) 1.06
Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res (2001) 1.06
Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A (2000) 1.06
Lamin B phosphorylation by protein kinase calpha and proteolysis during apoptosis in human leukemia HL60 cells. J Biol Chem (1998) 1.06
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res (1986) 1.06
The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract (1990) 1.06
HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem (1997) 1.05
Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin. Nucleic Acids Res (1993) 1.05
Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care (1997) 1.05
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Res (1997) 1.05